Your browser is no longer supported. Please, upgrade your browser.
HALO Halozyme Therapeutics, Inc. daily Stock Chart
Halozyme Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.56 Insider Own1.30% Shs Outstand137.19M Perf Week-2.14%
Market Cap3.64B Forward P/E19.68 EPS next Y1.42 Insider Trans1.88% Shs Float126.85M Perf Month19.85%
Income-80.10M PEG- EPS next Q0.23 Inst Own98.00% Short Float12.79% Perf Quarter55.17%
Sales164.40M P/S22.15 EPS this Y10.50% Inst Trans3.10% Short Ratio11.01 Perf Half Y44.94%
Book/sh0.42 P/B66.43 EPS next Y85.60% ROA-17.40% Target Price30.00 Perf Year66.57%
Cash/sh2.82 P/C9.89 EPS next 5Y47.00% ROE-48.90% 52W Range12.71 - 29.34 Perf YTD57.36%
Dividend- P/FCF- EPS past 5Y2.10% ROI-13.70% 52W High-4.91% Beta1.83
Dividend %- Quick Ratio10.20 Sales past 5Y21.10% Gross Margin71.60% 52W Low119.51% ATR1.05
Employees132 Current Ratio11.10 Sales Q/Q-55.40% Oper. Margin-44.90% RSI (14)64.68 Volatility3.18% 4.51%
OptionableYes Debt/Eq6.72 EPS Q/Q-465.30% Profit Margin-48.70% Rel Volume0.47 Prev Close28.00
ShortableYes LT Debt/Eq6.67 EarningsMay 11 AMC Payout- Avg Volume1.47M Price27.90
Recom2.40 SMA209.18% SMA5013.81% SMA20041.19% Volume691,600 Change-0.34%
Jul-01-20Initiated The Benchmark Company Buy $39
Feb-05-20Upgrade Piper Sandler Neutral → Overweight $18 → $27
Jan-09-20Upgrade BMO Capital Markets Market Perform → Outperform $17 → $24
Jan-08-20Initiated Goldman Buy $24
Nov-05-19Upgrade Barclays Underweight → Equal Weight $17 → $16
Oct-19-18Resumed Piper Jaffray Neutral
May-11-18Downgrade Barclays Equal Weight → Underweight $19
Jan-24-18Initiated Goldman Neutral
Oct-16-17Reiterated Piper Jaffray Overweight $26 → $29
Jan-06-17Downgrade Citigroup Buy → Neutral
Nov-03-16Initiated Deutsche Bank Buy $12
Dec-04-15Initiated Wells Fargo Outperform
Nov-18-15Initiated Citigroup Buy
Sep-22-15Initiated Barclays Overweight $27
Jun-22-15Reiterated JP Morgan Overweight $20 → $25
Mar-03-15Reiterated UBS Buy $16 → $21
Feb-18-15Reiterated MLV & Co Buy $15 → $20
Jan-08-15Reiterated MLV & Co Buy $12 → $15
Dec-24-14Initiated MLV & Co Buy $12
Jun-12-14Upgrade UBS Neutral → Buy $14 → $16
Jul-09-20 02:46PM  
Jul-01-20 07:20PM  
Jun-29-20 12:54PM  
Jun-22-20 08:00AM  
Jun-19-20 08:32AM  
Jun-17-20 05:08PM  
Jun-16-20 10:01AM  
Jun-13-20 07:09AM  
Jun-10-20 11:30AM  
Jun-04-20 12:35PM  
May-29-20 10:28AM  
May-28-20 08:01AM  
May-20-20 08:32AM  
May-19-20 08:37AM  
May-15-20 11:25AM  
May-14-20 04:01PM  
May-13-20 03:18AM  
May-12-20 09:52AM  
May-11-20 06:35PM  
May-08-20 10:34AM  
May-07-20 08:01AM  
May-01-20 03:16PM  
Apr-30-20 04:56PM  
Apr-28-20 05:05PM  
Apr-26-20 09:40PM  
Apr-13-20 08:44AM  
Apr-03-20 08:00AM  
Mar-29-20 05:44PM  
Mar-25-20 11:30AM  
Mar-19-20 10:30AM  
Mar-05-20 06:36PM  
Feb-28-20 08:39AM  
Feb-27-20 07:37AM  
Feb-26-20 04:01PM  
Feb-25-20 10:05AM  
Feb-24-20 05:45PM  
Feb-17-20 12:30PM  
Feb-10-20 04:01PM  
Feb-06-20 08:25AM  
Jan-14-20 08:00AM  
Jan-03-20 08:00AM  
Dec-12-19 11:30AM  
Dec-06-19 10:02AM  
Nov-20-19 05:28PM  
Nov-15-19 10:09AM  
Nov-14-19 08:27AM  
Nov-13-19 10:57PM  
Nov-12-19 05:45PM  
Nov-07-19 12:56PM  
Nov-05-19 10:32AM  
Nov-04-19 09:56AM  
Nov-01-19 09:05AM  
Oct-23-19 01:30PM  
Oct-21-19 08:00AM  
Oct-02-19 09:14AM  
Sep-23-19 08:00AM  
Sep-13-19 09:44PM  
Sep-02-19 10:48AM  
Aug-26-19 08:00AM  
Aug-08-19 10:58AM  
Aug-06-19 06:15PM  
Jul-30-19 10:38AM  
Jul-25-19 08:00AM  
Jul-23-19 04:01PM  
Jul-22-19 10:16AM  
Jul-19-19 07:00AM  
Jul-17-19 08:00AM  
Jul-12-19 11:59AM  
Jul-04-19 01:44PM  
Jun-25-19 08:00AM  
Jun-12-19 05:04PM  
Jun-11-19 04:37PM  
Jun-04-19 08:00AM  
Jun-03-19 01:34PM  
May-22-19 01:05AM  
May-21-19 07:46AM  
May-13-19 08:01AM  
May-07-19 09:23PM  
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; and National Institute of Allergy and Infectious Diseases. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LaBarre Michael J.SVP, Chief Technical OfficerMay 22Option Exercise7.1418,613132,897194,800May 22 06:39 PM
LaBarre Michael J.SVP, Chief Technical OfficerMay 20Option Exercise7.1421,387152,703197,574May 21 04:11 PM
LaBarre Michael J.SVP, Chief Technical OfficerMay 20Sale23.8021,387509,075176,187May 21 04:11 PM
Kelley Kenneth JDirectorMar 19Buy14.2352,629748,697277,553Mar 19 07:28 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 22Option Exercise0.008,8030179,231Feb 24 08:04 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 22Option Exercise0.0011,3920120,675Feb 24 08:03 PM
Torley HelenPresident and CEOFeb 22Option Exercise0.0039,3540510,033Feb 24 08:02 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 14Option Exercise0.005,7720172,423Feb 18 04:16 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 14Option Exercise0.007,8090111,983Feb 18 04:15 PM
Torley HelenPresident and CEOFeb 14Option Exercise0.0028,7300484,923Feb 18 04:14 PM
Matsuda MasaruSVP, General CounselFeb 12Option Exercise0.004,13008,619Feb 13 06:41 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 12Option Exercise0.007,8830169,376Feb 13 06:39 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 12Option Exercise0.0011,2620108,068Feb 13 06:38 PM
Torley HelenPresident and CEOFeb 12Option Exercise0.0032,7950472,452Feb 13 06:24 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 03Option Exercise0.0011,5590165,782Feb 04 04:24 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 03Option Exercise0.0023,1190105,081Feb 04 04:21 PM
Torley HelenPresident and CEOFeb 03Option Exercise0.0055,4870459,567Feb 04 04:18 PM
Hickey BenjaminSVP, Chief Commerical OfficerOct 01Option Exercise0.0020,216020,216Oct 01 07:10 PM
Chondros DimitriosSVP, Chief Medical OfficerAug 03Sale16.701,32822,17838,584Aug 05 08:11 PM